BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27717015)

  • 21. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
    Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
    Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low Counts of Plasmacytoid Dendritic Cells after Engraftment Are Associated with High Early Mortality after Allogeneic Stem Cell Transplantation.
    Gonçalves MV; Yamamoto M; Kimura EY; Colturato VA; de Souza MP; Mauad M; Ikoma MV; Novis Y; Rocha V; Ginani VC; Wanderley de Oliveira Felix OM; Seber A; Kerbauy FR; Hamerschlak N; Orfao A; Rodrigues CA
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1223-9. PubMed ID: 25792371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune cell subset counts associated with graft-versus-host disease.
    Podgorny PJ; Liu Y; Dharmani-Khan P; Pratt LM; Jamani K; Luider J; Auer-Grzesiak I; Mansoor A; Williamson TS; Ugarte-Torres A; Hoegh-Petersen M; Stewart DA; Daly A; Khan FM; Russell JA; Storek J
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):450-62. PubMed ID: 24406506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of ATG-F on B-cell reconstitution after hematopoietic stem cell transplantation.
    Roll P; Muhammad K; Stuhler G; Grigoleit U; Einsele H; Tony HP
    Eur J Haematol; 2015 Dec; 95(6):514-23. PubMed ID: 25677646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced Calcium Signaling Is Associated With Severe Graft-Versus-Host Disease: Results From Preclinical Models and From a Prospective EBMT Study.
    Riesner K; Cordes S; Peczynski C; Kalupa M; Schwarz C; Shi Y; Mertlitz S; Mengwasser J; van der Werf S; Peric Z; Koenecke C; Schoemans H; Duarte RF; Basak GW; Penack O
    Front Immunol; 2020; 11():1983. PubMed ID: 32849661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
    Yeral M; Kasar M; Boga C; Kozanoglu I; Ozdogu H; Sariturk C
    Exp Clin Transplant; 2015 Oct; 13(5):453-60. PubMed ID: 26103468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel targets in the treatment of chronic graft-versus-host disease.
    Im A; Hakim FT; Pavletic SZ
    Leukemia; 2017 Mar; 31(3):543-554. PubMed ID: 27899803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
    Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
    Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I; Bessmertny O; Harrison L; Cheung YK; Van de Ven C; del Toro G; Garvin J; George D; Bradley MB; Wolownik K; Wischhover C; Levy J; Skerrett D; Cairo MS
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
    Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
    Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
    Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
    Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
    Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.